Published on 21/12/2025
Understanding FDA Type A, B, and C Meetings: Differences and Case Examples
Overview of FDA Pre-Submission Meeting Types
Interacting with the U.S. Food and Drug Administration (FDA) is essential for successful regulatory navigation, especially in drug, biologic, or device development. The agency offers three structured meeting types — Type A, Type B, and Type C — each serving a specific purpose at different points in the product development lifecycle.
Knowing when to request each type and what to expect can significantly influence timelines, clinical program design, and eventual marketing approval.
FDA Type A Meetings: Crisis Resolution or Stalled Programs
Type A meetings are granted to help a sponsor address a stalled development program or to resolve critical regulatory issues that cannot wait. Examples include:
- Dispute resolution after a clinical hold
- Meeting following refusal-to-file (RTF) decision
- Type A meeting following a Complete Response Letter (CRL)
Timelines: FDA
Briefing package: Submitted at the time of meeting request or within 2 days of request acceptance.
FDA Type B Meetings: Key Milestone Interactions
Type B meetings are the most common form of pre-submission interaction. They occur at critical points such as:
- Pre-IND meeting
- End-of-Phase 2 (EOP2) meeting
- Pre-NDA or pre-BLA meeting
These meetings help confirm that safety, efficacy, and CMC strategies align with regulatory expectations.
Timelines: Meeting scheduled within 60 days of request. FDA responds within 14 days of request receipt.
Briefing package: Submitted at least 30 days before the confirmed meeting date.
FDA Type C Meetings: Other Development Topics
Type C meetings are for any topics not falling under Type A or B criteria. Examples include:
- Discussing a novel biomarker development plan
- Seeking clarification on post-marketing study designs
- Requesting early feedback on patient-reported outcomes
These are useful for advancing complex or innovative elements of the development program.
Timelines: Scheduled within 75 days of request; longer than Type A or B.
Continue with a Comparative Table and Real-World Case Studies
Comparative Table: FDA Meeting Types at a Glance
| Meeting Type | Purpose | Schedule Timeline | Example Use Case | Briefing Package Deadline |
|---|---|---|---|---|
| Type A | Resolve stalled programs or disputes | Within 30 days of request | Meeting after RTF or CRL | At time of request or within 2 days of acceptance |
| Type B | Key development milestones | Within 60 days of request | Pre-IND, EOP2, Pre-NDA | 30 days before meeting |
| Type C | Other development-related discussions | Within 75 days of request | Novel biomarker or device component | Agreed upon during meeting confirmation |
Case Study 1: Type A Meeting to Address CRL
A company received a Complete Response Letter (CRL) for a small-molecule oncology product due to concerns about CMC variability and missing safety data in an elderly subpopulation. A Type A meeting was requested to:
- Clarify what additional clinical trials were required
- Negotiate if bridging data could be used
- Understand timeline for resubmission
The meeting led to FDA agreement on a targeted patient population and allowed for re-analysis using real-world data, ultimately leading to a successful NDA resubmission.
Case Study 2: Type B Pre-IND Meeting
A biotech firm working on a monoclonal antibody for rare autoimmune disease held a pre-IND Type B meeting to:
- Confirm nonclinical study adequacy
- Discuss proposed starting dose in first-in-human study
- Clarify the need for additional reproductive toxicology studies
The company received valuable input, avoiding an unnecessary animal study and confirming their clinical protocol design.
Case Study 3: Type C Meeting on Patient-Reported Outcomes
A sponsor sought feedback on a new quality-of-life endpoint for a chronic pain study. Since this topic didn’t qualify for Type A or B, a Type C meeting was arranged. FDA provided:
- Recommendations on endpoint validation strategy
- Advice on integrating PROs into labeling claims
This early input helped secure FDA agreement on PRO methodology, critical to Phase 3 success.
Strategic Considerations for Meeting Type Selection
Type A: Use judiciously for major regulatory roadblocks. These meetings are rare and require strong justification.
Type B: Always plan ahead. These should be part of your regulatory roadmap and aligned with key submission milestones.
Type C: Ideal for innovative development approaches, risk assessments, or clarifications not tied to formal submissions.
External References and Tools
For examples of meeting types used in global regulatory submissions, visit the Australian New Zealand Clinical Trials Registry to review trial protocols and regulatory pathways involving early agency engagement.
Conclusion: Matching Meeting Type to Development Stage
Properly identifying and requesting the right type of FDA meeting is critical to a sponsor’s regulatory success. Each meeting type serves a distinct purpose, with differing expectations for timelines, content, and feedback. Regulatory teams should develop a long-term meeting strategy, integrated with their submission plan and product development milestones.
When planned effectively, these meetings serve not just as checkpoints but as accelerators toward successful product approval.